Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-γ

International Journal of Biochemistry and Cell Biology

Volumn 38, Issue 5-6, 2006, Pages 766-781

  Pershadsingh, Harrihar A ^a,b,c  

^a KERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin II antagonist; Angiotensin II receptor; Insulin resistance; Metabolic syndrome; Peroxisome proliferator activated receptor

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CIGLITAZONE; DIHYDROPYRIDINE; EPROSARTAN; FARGLITAZAR; HYDROCHLOROTHIAZIDE; INSULIN; IRBESARTAN; LOSARTAN; NATEGLINIDE; NIFEDIPINE; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RAGAGLITAZAR; ROSIGLITAZONE; TELMISARTAN; TROGLITAZONE; UNINDEXED DRUG; VALSARTAN;

ADIPOGENESIS; ATHEROGENESIS; BLOOD PRESSURE REGULATION; CARCINOGENESIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; ENERGY EXPENDITURE; FLUID RETENTION; GENE EXPRESSION; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MEDICAL INFORMATION; META ANALYSIS; METABOLIC SYNDROME X; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERIPHERAL EDEMA; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOSIS; WEIGHT GAIN;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BIPHENYL COMPOUNDS; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; LOSARTAN; METABOLIC SYNDROME X; PPAR GAMMA; TETRAZOLES;

EID: 33644858190     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2005.08.006     Document Type: Review

References (123)

1. M. Abdelrahman, A. Sivarajah, and C. Thiemermann Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock Cardiovascular Research 65 2005 772 781
2. L. Abu-Elheiga, M.M. Matzuk, K.A. Abo-Hashema, and S.J. Wakil Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2 Science 291 2001 2613 2616
3. M. Adamczak, A. Wiecek, T. Funahashi, J. Chudek, F. Kokot, and Y. Matsuzawa Decreased plasma adiponectin concentration in patients with essential hypertension American Journal of Hypertension 16 2003 72 75
4. K.G. Alberti, and P.Z. Zimmet Definition, diagnosis and classification of diabetes mellitus and its complications Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation Diabetic Medicine 15 1998 539 553
5. T. Albrektsen, K.S. Frederiksen, W.E. Holmes, E. Boel, K. Taylor, and J. Fleckner Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation Diabetes 51 2002 1042 1051
6. American Diabetes Association Position Statement Diagnosis and Classification of Diabetes Mellitus Diabetes Care 27 2004 S5 S10
7. E.A. Anderson, R.P. Hoffman, T.W. Balon, C.A. Sinkey, and A.L. Mark Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans Journal of Clinical Investigation 87 1991 2246 2252
8. Y. Arita, S. Kihara, N. Ouchi, K. Maeda, H. Kuriyama, and Y. Okamoto Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell Circulation 105 2002 2893 2898
9. Y. Arita, S. Kihara, N. Ouchi, M. Takahashi, K. Maeda, and J. Miyagawa Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity Biochemical and Biophysical Research Communication 257 1999 79 83
10. 2+ mobilization and cell proliferation in vascular smooth muscle cells British Journal of Pharmacology 128 1999 673 683
11. S.C. Benson, H.A. Pershadsingh, C.I. Ho, A. Chittiboyina, P. Desai, and M. Pravenec Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity Hypertension 43 2004 993 1002
12. J.P. Berger, and D.E. Moller The mechanisms of action of PPARs Annual Review of Medicine 53 2002 409 435
13. J.P. Berger, T.E. Akiyama, and P.T. Meinke PPARs: Therapeutic targets for metabolic disease Trends in Pharmacological Sciences 26 2005 244 251
14. J.P. Berger, A.E. Petro, K.L. Macnaul, L.J. Kelly, B.B. Zhang, and K. Richards Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator Molecular Endocrinology 17 2003 662 676
15. C. Blanquart, O. Barbier, J.C. Fruchart, B. Staels, and C. Glineur Peroxisome proliferator-activated receptors: Regulation of transcriptional activities and roles in inflammation Journal of Steroid Biochemistry and Molecular Biology 85 2003 267 273
16. P. Bramlage, D. Pittrow, and W. Kirch The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: An observational study in 16 600 patients in primary care Current Medical Research Opinion 20 2004 1625 1631
17. A.J. Cameron, J.E. Shaw, and P.Z. Zimmet The metabolic syndrome: Prevalence in worldwide populations Endocrinology and Metabolism Clinics of North America 33 2004 351 375
18. H.S. Camp, O. Li, S.C. Wise, Y.H. Hong, C.L. Frankowski, and X. Shen Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone Diabetes 49 2000 539 547
19. C. Cardillo, S.S. Nambi, C.M. Kilcoyne, W.K. Choucair, A. Katz, and M.J. Quon Insulin stimulates both endothelin and nitric oxide activity in the human forearm Circulation 100 1999 820 825
20. R. Clasen, M. Schupp, A. Foryst-Ludwig, C. Sprang, M. Clemenz, and M. Krikov PPAR{gamma}-activating angiotensin type-1 receptor blockers induce adiponectin Hypertension 46 2005 137 143
21. M. Clemenz, J. Frank, M. Schupp, M. Goebel, T. Unger, and U. Kintscher The PPARγ-activating ARB irbesartan stimulates expression of the insulin-signaling protein CAP and enhances insulin-induced glucose uptake 2004 American Heart Association Scientific Sessions New Orleans, Louisiana [Abstract #3850]
22. T.A. Cock, S.M. Houten, and J. Auwerx Peroxisome proliferator-activated receptor-gamma: Too much of a good thing causes harm EMBO Reports 5 2004 142 147
23. J.A. Crouse, G.E. Elliott, T.L. Burgess, L. Chiu, L. Bennett, and J. Moore Altered cell surface expression and signaling of leptin receptors containing the fatty mutation Journal of Biological Chemistry 273 1998 18365 18373
24. B. Dahlof, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, and U. de Faire Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol Lancet 359 2002 995 1003
25. M. de Gasparo, K.J. Catt, T. Inagami, J.W. Wright, and T. Unger International Union of Pharmacology XXIII. The angiotensin II receptors Pharmacological Reviews 52 2000 415 472
26. T.E. Delea, J.S. Edelsberg, M. Hagiwara, G. Oster, and L.S. Phillips Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: A retrospective cohort study Diabetes Care 26 2003 2983 2989
27. G. Derosa, A.F. Cicero, G. Bertone, M.N. Piccinni, E. Fogari, and L. Ciccarelli Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: A 12-month, randomized, double-blind study Clinical Therapeutics 26 2004 1228 1236
28. G. Derosa, P.D. Ragonesi, A. Mugellini, L. Ciccarelli, and R. Fogari Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: A randomized, double-blind, placebo-controlled 12-month study Hypertension Research 27 2004 264 457
29. R.H. Eckel, S.M. Grundy, and P.Z. Zimmet The metabolic syndrome Lancet 365 2005 1415 1428
30. E.S. Ford, W.H. Giles, and A.H. Mokdad Increasing prevalence of the metabolic syndrome among U.S. adults Diabetes Care 27 2004 2444 2449
31. M. Fujimoto, H. Masuzaki, T. Tanaka, S. Yasue, T. Tomita, and K. Okazawa An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes FEBS Letters 576 2004 492 497
32. T. Funahashi, T. Nakamura, I. Shimomura, K. Maeda, H. Kuriyama, and M. Takahashi Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity Internal Medicine 38 1999 202 206
33. D.L. Gerhold, F. Liu, G. Jiang, Z. Li, J. Xu, and M. Lu Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists Endocrinology 143 2002 2106 2118
34. C.B. Granger, J.J. McMurray, S. Yusuf, P. Held, E.L. Michelson, and B. Olofsson Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: The CHARM-Alternative trial Lancet 362 2003 772 776
35. G. Grassi, G. Seravalle, R. Dell'Oro, F.Q. Trevano, M. Bombelli, F. Scopelliti CROSS Study Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study Journal of Hypertension 21 2003 1761 1769
36. S.M. Grundy Obesity metabolic syndrome, and cardiovascular disease Journal of Clinical Endocrinology and Metabolism 89 2004 2595 2600
37. H.J. Harwood Jr. Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome Current Opinion in Investigational Drugs 5 2004 283 289
38. E.J. Henriksen, S. Jacob, T.R. Kinnick, M.K. Teachey, and M. Krekler Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats Hypertension 38 2001 884 890
39. T.J. Heppner, A.D. Bonev, D.M. Eckman, M.F. Gomez, G.V. Petkov, and M.T. Nelson Novel PPARgamma agonists GI262570, GW 7845 GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries Pharmacology 73 1929 15 22
40. N.K. Hollenberg Considerations for management of fluid dynamic issues associated with thiazolidinediones American Journal of Medicine 115 2003 S111 S115
41. S. Honjo, Y. Nichi, Y. Wada, Y. Hamamoto, and a.H. Koshiyam Possible beneficial effect of telmisartan on glycemic control in diabetic subjects Diabetes Care 28 2005 498
42. G.S. Hotamisligil, N.S. Shargill, and B.M. Spiegelman Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance Science 259 1993 87 91
43. K. Hotta, T. Funahashi, Y. Arita, M. Takahashi, M. Matsuda, and Y. Okamoto Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients Arteriosclerosis, Thrombosis and Vascular Biology 20 2000 1595 1599
44. K.J. Hunt, R.G. Resendez, K. Williams, S.M. Haffner, M.P. Stern San Antonio Heart Study National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study Circulation 110 2004 1251 1257
45. International Diabetes Federation consensus worldwide definition of the metabolic syndrome, 14 April 2005: www.idf.org/webdata/docs/Metac_syndrome_def. pdf.
46. C. Jiang, A.T. Ting, and B. Seed PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines Nature 391 1998 82 86
47. T. Kadowaki Insights into insulin resistance and type 2 diabetes from knockout mouse models Journal of Clinical Investigation 106 2000 459 465
48. T. Kazumi, A. Kawaguchi, K. Sakai, T. Hirano, and G. Yoshino Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure Diabetes Care 25 2002 971 976
49. D.E. Kelley, J. He, E.V. Menshikova, and V.B. Ritov Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes Diabetes 51 2002 2944 2950
50. P.A. Kern, M. Saghizadeh, J.M. Ong, R.J. Bosch, R. Deem, and R.B. Simsolo The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase Journal of Clinical Investigation 95 1995 2111 2119
51. S. Kojima, T. Funahashi, H. Maruyoshi, O. Honda, S. Sugiyama, and H. Kawano Levels of the adipocyte-derived plasma protein, adiponectin, have a close relationship with atheroma Thrombosis Research 115 2005 483 490
52. N. Kubota, Y. Terauchi, H. Miki, H. Tamemoto, T. Yamauchi, and K. Komeda PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance Molecular Cell 4 1999 597 609
53. M. Kumada, S. Kihara, S. Sumitsuji, T. Kawamoto, S. Matsumoto, N. Ouchi Osaka CAD Study Group Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men Arteriosclerosis, Thrombosis and Vascular Biology 23 2003 85 89
54. T.W. Kurtz, and M. Pravenec Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: Beyond the renin-angiotensin system Journal of Hypertension 22 2004 2253 2261
55. D.E. Laaksonen, H.M. Lakka, L.K. Niskanen, G.A. Kaplan, J.T. Salonen, and T.A. Lakka Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study American Journal of Epidemiology 156 2002 1070 1077
56. H.M. Lakka, D.E. Laaksonen, T.A. Lakka, L.K. Niskanen, E. Kumpusalo, and J. Tuomilehto The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men Journal of the American Medical Association 288 2002 2709 2716
57. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) Journal of Biological Chemistry 270 1995 12953 12956
58. L.H. Lindholm, M. Persson, P. Alaupovic, B. Carlberg, A. Svensson, and O. Samuelsson Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study) Journal of Hypertension 21 2003 1563 1574
59. H. Lithell, L. Hansson, I. Skoog, D. Elmfeldt, A. Hofman, and B. Olofsson The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial Journal of Hypertension 21 2003 875 886
60. T. Littlejohn, R. Saini, K. Kassler-Taub, S.G. Chrysant, and T. Marbury Long-term safety and antihypertensive efficacy of irbesartan: Pooled results of five open-label studies Clinical Experimental Hypertension 21 1999 1273 1295
61. M.R. Marino, and N.N. Vachharajani Pharmacokinetics of irbesartan are not altered in special populations Journal Cardiovascular Pharmacology 40 2002 112 122
62. M. Matsuda, I. Shimomura, M. Sata, Y. Arita, M. Nishida, and N. Maeda Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis Journal of Biological Chemistry 277 2002 37487 37491
63. Y. Matsuzawa, T. Funahashi, and T. Nakamura Molecular mechanism of metabolic syndrome X: Contribution of adipocytokines adipocyte-derived bioactive substances Annals of the New York Academy of Sciences 892 1999 146 154
64. Y. Matsuzawa Adiponect Identification physiology clinical relevance in metabolic and vascular disease Atherosclerosis 6 2005 7 14
65. N.J. McKenna, and B.W. O'Malley Minireview: Nuclear receptor coactivators-an update Endocrinology 143 2002 2461 2465
66. J.J. McMurray, J. Ostergren, K. Swedberg, C.B. Granger, P. Held, and E.L. Michelson Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771
67. F.H. Messerli Vasodilatory edema: A common side effect of antihypertensive therapy Current Cardiology Reports 4 2002 479 482
68. M.C. Michel, H. Bohner, J. Koster, R. Schafers, and U. Heemann Safety of telmisartan in patients with arterial hypertension: An open-label observational study Drug Safety 27 2004 335 344
69. A.R. Miller, and G.J. Etgen Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome Expert Opinion in Investigational Drugs 12 2003 1489 1500
70. A.W. Miller, C. Tulbert, M. Puskar, and D.W. Busija Enhanced endothelin activity prevents vasodilation to insulin in insulin resistance Hypertension 40 2002 78 82
71. Y. Miura, N. Yamamoto, S. Tsunekawa, S. Taguchi, Y. Eguchi, and N. Ozaki Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: Metabolic and antiatherogenic consequences Diabetes Care 28 2005 757 758
72. Y. Miyazaki, A. Mahankali, E. Wajcberg, M. Bajaj, L.J. Mandarino, and R.A. DeFronzo Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients Journal of Clinical Endocrinology and Metabolism 89 2004 4312 4319
73. D.E. Moller New drug targets for Type 2 diabetes and the metabolic syndrome Nature 414 2001 821 827
74. D.E. Moller, and K.D. Kaufman Metabolic syndrome: A clinical and molecular perspective Annual Review of Medicine 56 2005 45 62
75. S. Mudaliar, A.R. Chang, and R.R. Henry Thiazolidinediones, peripheral edema, and type 2 diabetes: Incidence, pathophysiology, and clinical implications Endocrinology Practice 9 2003 406 416
76. NCEP/ATP III: Executive Summary of the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (2001). Journal of the American Medical Association, 285, 2486-2497.
77. R.W. Nesto, D. Bell, R.O. Bonow, V. Fonseca, S.M. Grundy, and E.S. Horton Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association Diabetes Care 27 2004 256 263
78. J.L. Oberfield, J.L. Collins, C.P. Holmes, D.M. Goreham, J.P. Cooper, and J.E. Cobb A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation Proceedings of the National Academy of Sciences USA 96 1999 6102 6106
79. J.M. Olefsky Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists Journal of Clinical Investigation 106 2000 467 472
80. N. Ouchi, S. Kihara, T. Funahashi, T. Nakamura, M. Nishida, and M. Kumada Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue Circulation 107 2003 671 674
81. N. Ouchi, S. Kihara, T. Funahashi, Y. Matsuzawa, and K. Walsh Obesity, adiponectin and vascular inflammatory disease Current Opinion in Lipidology 14 2003 561 566
82. V. Papademetriou The potential role of AT(1)-receptor blockade in the prevention and reversal of atherosclerosis Journal of Human Hypertension 16 Suppl. 3 2002 S34 S41
83. Y.W. Park, S. Zhu, L. Palaniappan, S. Heshka, M.R. Carnethon, and S.B. Heymsfield The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey 1988-1994 Archives of Internal Medicine 163 2003 427 436
84. H.A. Pershadsingh Pharmacological peroxisome proliferator-activated receptorgamma ligands: Emerging clinical indications beyond diabetes Expert Opinion in Investigational Drugs 8 1999 1859 1872
85. Pershadsingh, H.A. (2003). Novel PPAR ligands that do not cause fluid retention, edema or congestive heart failure. United States Patent Application 20040127443, patent pending.
86. H.A. Pershadsingh Peroxisome proliferator-activated receptor-gamma: Therapeutic target for diseases beyond diabetes: Quo vadis? Expert Opinion in Investigational Drugs 13 2004 215 228
87. H.A. Pershadsingh, and T.W. Kurtz Insulin-sensitizing effects of telmisartan: Implications for treating insulin-resistant hypertension and cardiovascular disease Diabetes Care 27 2004 1015
88. H.A. Pershadsingh, S.C. Benson, C.I. Ho, and T.W. Kurtz Identification of PPAR-gamma Activators That Do Not Promote Fluid Retention and Edema: Implications for Treating Insulin Resistant Hypertension and the Metabolic Syndrome Symposium on the Role of Nuclear Receptors in Cardiovascular Disease The Endocrine Society, Hot Topics, San Diego, California 2003 29 [abstract]
89. H.A. Pershadsingh, J. Szollosi, S. Benson, W.C. Hyun, B.G. Feuerstein, and T.W. Kurtz Effects of ciglitazone on blood pressure and intracellular calcium metabolism Hypertension 21 1993 1020 1023
90. P. Piatti, G. Fragasso, L.D. Monti, A. Caumo, C. Van Phan, and G. Valsecchi Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries: Comparison with subjects with insulin resistance syndrome and normal controls Journal of the American College of Cardiology 34 1999 1452 1460
91. Prescribing information (2005) Actos® (pioglitazone hydrochloride) Tablets, Takeda Chemical Industries Ltd, Osaka, Japan.
92. Prescribing information (2005) Avandia® (rosiglitazone maleate) Tablets, SmithKline Beecham Pharmaceuticals, Philadelphia, PA, USA.
93. G.M. Reaven Banting lecture: Role of insulin resistance in human disease Diabetes 37 1988 1595 1607
94. M. Ricote, A.C. Li, T.M. Willson, C.J. Kelly, and C.K. Glass The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation Nature 391 1998 79 82
95. P.M. Ridker, P.W. Wilson, and S.M. Grundy Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109 2004 2818 2825
96. A.W. Roberts, A. Thomas, A. Rees, and M. Evans Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: Current evidence and future directions Current Opinion in Lipidology 14 2003 567 573
97. M.A. Sarayba, L. Li, T. Tungsiripat, N.H. Liu, P.M. Sweet, and A.J. Patel Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand Experimental Eye Research 80 2005 435 442
98. H. Satoh, K. Tsukamoto, Y. Hashimoto, N. Hashimoto, M. Togo, and M. Hara Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: A new possible role of PPARgamma on vascular endothelial function Biochemical and Biophysical Research Communications 254 1999 757 763
99. A.J. Scheen Renin-angiotensin inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials Diabetes & Metabolism 30 2004 487 496
100. M. Schupp, R. Gineste, M. Clemenz, H. Witt, J. Janke, and S. Helleboid PPARγ activating angiotensin receptor blockers exhibit differential cofactor recruitment and induce a divergent gene expression profile in 3T3-L1 adipocytes Proceedings of the Third International Symposium on PPAR Efficacy and Safety Monte Carlo 2005 11 [abstract]
101. M. Schupp, J. Janke, R. Clasen, T. Unger, and U. Kintscher Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity Circulation 109 2004 2054 2057
102. H.D. Sesso, J.E. Buring, N. Rifai, G.J. Blake, J.M. Gaziano, and P.M. Ridker C-reactive protein and the risk of developing hypertension. Journal of the American Medical Association 290 2003 2945 2951
103. B.G. Shearer, and W.J. Hoekstra Recent advances in peroxisome proliferator-activated receptor science Current Medicinal Chemistry 10 2003 267 280
104. B.K. Skrumsager, K.K. Nielsen, M. Muller, G. Pabst, P.G. Drake, and B. Edsberg Ragaglitazar: The pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes Journal of Clinical Pharmacology 43 2003 1244 1256
105. G.R. Smith, and S. Missailidis Cancer, inflammation and the AT1 and AT2 receptors Journal of Inflammation (London) 1 2004 3 15
106. 14C]telmisartan in healthy volunteers Journal of Clinical Pharmacology 40 2000 1312 1322
107. Y. Suzuki, M. Ruiz-Ortega, O. Lorenzo, M. Ruperez, V. Esteban, and J. Egido Inflammation and angiotensin II International Journal of Biochem istry and Cell Biology 35 2003 881 900
108. D.M. Tham, Y.X. Wang, and J.C. Rutledge Modulation of vascular inflammation by PPARs Drug News Perspective 16 2003 109 116
109. J. Tordjman, G. Chauvet, J. Quette, E.G. Beale, C. Forest, and B. Antoine Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells Journal of Biological Chemistry 278 2003 18785 18790
110. R.M. Touyz, and C. Berry Recent advances in angiotensin II signaling Brazilian Journal of medical Biological Research 35 2002 1001 1015
111. Vidal, J., Morinigo, R., Codoceo, V.H., Casamitjana, R., Pellitero, S., & Gomis, R. (2005). The importance of diagnostic criteria in the association between the metabolic syndrome and cardiovascular disease in obese subjects. International Journal of Obesity and Related Metabolic Disorders, March 8 [Epub ahead of print].
112. Vitale, C., Mercuro, G., Castiglioni, C., Cornoldi, A., Tulli, A., Fini, M., et al. (2005). Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovascular Diabetology, 4, 6 (8 p.).
113. M.R. Weir Incidence of pedal edema formation with dihydropyridine calcium channel blockers: Issues and practical significance Journal of Clinical Hypertension (Greenwich) 5 2003 330 335
114. World Health Organization: Report of a WHO Consultation A. Alwan H. King Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1. Diagnosis and Classification of Diabetes Mellitus 1999 World Health Organization, Department of Noncommunicable Disease Surveillance Geneva 1 59
115. T.M. Willson, P.J. Brown, D.D. Sternbach, and B.R. Henke The PPARs: From orphan receptors to drug discovery Journal of Medicinal Chemistry 43 2000 527 550
116. T.M. Willson, M.H. Lambert, and S.A. Kliewer Peroxisome proliferator-activated receptor gamma and metabolic disease Annual Review of Biochemistry 70 2001 341 367
117. Y. Yamamoto, H. Hirose, I. Saito, M. Tomita, M. Taniyama, and K. Matsubara Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population Clinical Sciences (London) 103 2002 137 142
118. T. Yamauchi, J. Kamon, H. Waki, K. Murakami, K. Motojima, and K. Komeda The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance Journal of Biological Chemistry 276 2001 41245 41254
119. W.S. Yang, C.Y. Jeng, T.J. Wu, S. Tanaka, T. Funahashi, and Y. Matsuzawa Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients Diabetes Care 25 2002 376 380
120. D.A. York, S. Rossner, I. Caterson, C.M. Chen, W.P. James, and S. Kumanyika American Heart Association. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke. Group I. Worldwide demographics of obesity Circulation 110 2004 463 470
121. C. Yu, K. Markan, K.A. Temple, D. Deplewski, M.J. Brady, and R.N. Cohen The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis Journal of Biological Chemistry 280 2005 13600 13605
122. J.S. Yudkin Adipose tissue, insulin action and vascular disease: Inflammatory signals International Journal of Obesity and Related Metabolic Disorders 27 2003 S25 S28
123. P. Zimmet, K.G. Alberti, and J. Shaw Global and societal implications of the diabetes epidemic Nature 414 2001 782 787